Following on from information provided to NICE by the company in January 2019, the appraisal of Leukaemia (acute myeloid, IDH2 positive) - enasidenib (after 2 therapies) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1455
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 November 2022 | Discontinued. Following on from information provided to NICE by the company in January 2019, the appraisal of Leukaemia (acute myeloid, IDH2 positive) - enasidenib (after 2 therapies) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 06 October 2020 | Note added to the project documents |
| 01 February 2019 | Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps |
| 31 July 2017 | In progress. Topic referred |
| 13 July 2017 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual